Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Lifecare AS ( (DE:LFC0) ) has provided an update.
Lifecare ASA has released its Q1 2025 financial report, highlighting progress towards launching its innovative Continuous Glucose Monitor (CGM) technology. The company is advancing towards a product design freeze with improved sensor sensitivity and manufacturability, aiming for market entry by 2027. Lifecare is leveraging the veterinary market as an early commercialization opportunity and plans to build a customer base of 75,000 patients by 2030. The company is set to open a production facility in Mainz, Germany, and continues to enhance its B2B model with strategic partnerships for sales and distribution.
More about Lifecare AS
Lifecare ASA is a clinical stage medical sensor company focused on developing next-generation Continuous Glucose Monitoring (CGM) systems. Utilizing osmotic pressure as a sensing principle, Lifecare’s technology is designed for monitoring various body analytes in humans and pets, with a particular emphasis on implantable CGMs.
Average Trading Volume: 25,879
Current Market Cap: NOK126.8M
For a thorough assessment of LFC0 stock, go to TipRanks’ Stock Analysis page.